Background. Transforming growth factor-b1 (TGF-b1) stimulates the deposition of extracellular matrix (ECM), which is a hallmark in end-stage renal disease. The importance of TGF-b1-induced changes in protease activity in this process is not fully elucidated. TGF-b1 up-regulates plasminogen activator inhibitor type 1 (PAI-1), which lowers matrix degradation. Our aim was to investigate the importance of PAI-1 in TGF-b1induced kidney disease.
of extracellular matrix (ECM) in the form of glomerulosclerosis and interstitial fibrosis. This results from a disturbed balance between matrix synthesis and matrix degradation.
Transforming growth factor-b1 (TGF-b1) is synthesized in increased amounts in both experimental and human kidney diseases such as diabetic nephropathy, glomerulonephritis and focal segmental glomerulosclerosis [1] [2] [3] [4] . In addition, transgenic mice with renal overexpression of TGF-b1 develop glomerulosclerosis and interstitial fibrosis associated with kidney malfunction [5] [6] [7] . Therefore, TGF-b1 plays a key role in the pathogenesis of kidney disease and the progression to ESRD.
One of the important effects of TGF-b1 in the pathogenesis of renal disease is regulation of ECM metabolism [8] . Transforming growth factor-b1 augments the ECM deposition through increased synthesis of ECM molecules such as collagen, fibronectin, and laminin by glomerular, tubular, and interstitial cells, as well as influencing the degradation of ECM [7, [9] [10] [11] [12] . One pathway by which TGF-b1 can modulate the activity of ECM degrading proteases is through the plasmin system.
Plasmin is a serine protease that is secreted in an inactive form as plasminogen, which is activated by tissue type plasminogen activator (t-PA) and urokinase type plasminogen activator (u-PA). This activation is inhibited by plasminogen activator inhibitor type 1 to 3 (PAI-1-PAI-3). The best described effect of plasmin is degradation of fibrin, but it also contributes to fibronectin and laminin breakdown. Plasmin also affects ECM metabolism indirectly through the activation of matrix metalloproteases (MMPs), which are the principal ECM degrading proteases [13, 14] . Furthermore, recent publications suggest that protease independent effects of plasmin and PAI, such as modulation of macrophage invasion, also are of importance [15, 16] . Finally, t-PA and u-PA might have plasmin-independent biological effects such as activation of latent TGF-b1 and MMPs [13, 17] .
Transforming growth factor-b1 is a potent regulator of the plasmin system through stimulation of PAI-1 gene expression [18] . The level of PAI-1 expression is very low in the normal kidney. Conversely, it has been shown to be elevated in many renal diseases, such as glomerulonephritis, diabetic nephropathy, and focal segmental glomerulosclerosis [14, [19] [20] [21] . Furthermore, we have shown that PAI-1 immune staining is increased in glomeruli of TGF-b1 transgenic mice [6] . These observations led to the hypothesis that TGF-b1-induced PAI-1 expression could decrease ECM degradation and contribute to the fibrotic process. This assumption has been investigated experimentally in different models, including the unilateral ureteral obstruction and glomerulonephritis [16, [22] [23] [24] , but to our knowledge not in more slowly developing kidney diseases. Thus, in the present investigation we elucidated the importance of PAI-1 in the progression of TGF-b1-induced renal disease. This was done by investigating the effect of PAI-1 knockout (PAI-1 KO) on the development of renal disease in transgenic mice with renal overexpression of TGF-b1. Using reverse transcriptionpolymerase chain reaction (RT-PCR), stereology, and biochemistry we demonstrated that the TGF-b1-induced increase in basal membrane thickening, mesangial expansion, and collagen deposition was attenuated by PAI-1 deficiency.
METHODS Animals
PAI-1 knockout mice on a 129sv × C57 background were backcrossed with TGF-b1 transgenic and nontransgenic mice on C57 BL/6J background obtaining 93% C57 pups [5, 25] . The genotype of the mice was established by PCR on DNA from tail biopsies. PAI-1 deficient (PAI-1 KO) and PAI-1 wild-type (PAI-1 WT) mice of both TGF-b1 transgenic (TGF-b1+) and TGF-b1 non-transgenic (TGF-b1−) genotype were used in the experiments. The mice were housed at the animal facility at the University of Aarhus and handled according to the guidelines and procedures approved by the Animal Experiments Inspectorate, Denmark (#1999/561-218) and the Danish Working Environment Service (#BK 2001-0011479/8). The animals were kept at 21 • C with a 12-hour day/night cycle and were given free access to standard chow and water. All mice were sacrificed by cervical dislocation.
Collection of material for glomerular morphology, functional investigations, and immunohistochemistry
Spot urine was collected from 10-to 16-and 34-weekold mice of each genotype. The 10-and 16-week-old mice were weighed and placed in individual metabolic cages and the water intake and the urine production were recorded during 24 hours. The right or left kidney was randomly sampled and immersion fixed for stereology in 3/4 thyrode buffer containing 1% glutaraldehyde and 3% paraformaldehyde. One half of the other kidney was placed in OCT-compound (Seikagaku Co., Tokyo, Japan) and snap frozen in liquid nitrogen, while the other half was fixed in paraformaldehyde and embedded in paraffin.
Glomerular morphology
Ten-and 16-week-old mice of each of the four genotypes were chosen randomly from the mice above. To eliminate any possible sex-related variation in the glomerular number the 10-week-old mice (N = 5-6 in each group) were males only. The 16-week-old mice (N = 6 in each group) were sex-matched.
Glomerular number and volume
The kidney was cut into 1 mm slices, and every third slice was sampled and embedded in the same plastic block. The slices were cut completely in 15 lm thick sections. Every ninth and the next section were collected as a disector pair. One 3 lm thick section was cut after disector pair number 3 and 6 [26] . The glomerular number was counted using the physical fractionator on a computerized microscope system (CAST, Olympus, Denmark) at ×113 total magnification on the screen [27, 28] . The glomerular number was estimated as:
BSF is block sampling fraction ( = 1/3), SSF is the section sampling fraction ( = 1/9), dx and dy is the section step length (3500 lm), a(frame) is the area of the counting frame, and Q − (glom) the number of glomeruli counted. The glomerular density Nv(glom/kidney) was estimated in a disector as:
In this formula Q − is the number of glomeruli counted, t is thickness of the disector sections, (a/p) is the area per point, and P(kidney) is the number of points overlaying the kidney.
The volume fraction of glomeruli was estimated on the two 3 lm thick sections using point counting, with 6 points for the total kidney and 150 points for the glomeruli. The mean glomerular volume was then calculated as:
Mesangial volumes and basement membrane thickness (BMT)
Tissue biopsies were punched out randomly from the cortex using a device with equally spaced holes. The biopsies were contrasted with osmium, embedded in epon, and 2-to 3-lm thin sections were cut until at least one glomerulus appeared. Then 50 nm sections were cut and examined with a digitalized Philips CM10 electron microscope (SIS 3.0; Philips, Amsterdam, The Netherlands). Glomeruli were photographed with a Kodak 1.6 camera (Kodak, Rochester, NY, USA). The mesangial volume fractions [Vv(mes/glom) and Vv(mes/tuft)] were point counted on a ×3400 original magnification using a 1:9 grid. The glomerular area was defined as the polygon obtained when the outer capillary profiles were connected by straight lines. The tuft area was defined as everything enclosed by the glomerular basement membrane (GBM), thereby excluding the epithelial cells and urinary space. Glomerular profiles with large vascular poles were excluded to reduce the variation. The BMT was measured where it intersected with test lines on ×7900 original magnification and the harmonically mean was calculated [29] .
Assessment of renal disease by urinary albumin:creatinine ratio
The urinary content of albumin was determined by radioimmunoassay as previously described using rat antibody and standards [30] . Rabbit anti-rat albumin antibody was purchased from Nordic Pharmaceuticals and Diagnostics (Tilburg, The Netherlands). For standard and iodination, a globulin-free rat albumin was obtained from Sigma Chemicals (St. Louis, MO, USA). The detection limit of the assay was defined as the lowest standard (0.039 lg/mL). The urinary creatinine content was measured by a commercial available assay according to the supplier (Sigma, Munich, Germany) and the albumin:creatinine ratio was calculated.
Immunohistochemistry
Paraffin sections. Sections were deparaffinized, rehydrated, and blocked with 0.02 mol/L glycine. The epitopes were demasked by microwave treatment for 12 minutes in a 10 mmol/L citrate buffer, pH 6.0 (collagen types I and III) or for 20 minutes in 0.5 mol/L Tris-HCl, pH 10 (PAI-1). After blockage with 2% normal serum, primary antibody was added against collagen type I (1:100; Biodesign, Saco, ME, USA), collagen type III (1:15; Chemicon, Temecula, CA, USA), Mac 3 (1:6; BD Pharmingen TM , San Jose, CA, USA), or PAI-1 (1:80; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Thereafter, sections were incubated with biotin labeled secondary antibody (1:200; Vector Laboratories, Burlingame, CA, USA), which was detected by the ABC kit (Vector Laboratories) and 3,3 diaminobenzidine (Sigma-Aldrich).
Frozen sections. Five lm thick sections were blocked with 2% normal serum and thereafter incubated for 30 minutes at room temperature with antibodies against collagen type IVa1-2 (1:100; Southern Biotechnology, Birmingham, AL, USA), laminin b2 (1:200; gift from Dr. R. Timpl, Max-Planch-Institute, Germany), or fibronectin (1:400; Biogenesis, Poole, UK). Afterward, the sections were treated as above. In all immunostainings, omission of the primary antibody served as negative control. A LPS-stimulated murine macrophage cell line (IC-21) (ATCC, Manassas, VA, USA) served as positive control for the Mac3 staining.
Assessment of collagen content by the hydroxyproline method
Kidneys from 16-and 34-week-old mice from each genotype were collected and defatted in chloroform:methanol 2:1 including protease inhibitors, for 21 hours at 4 • C. Then, 200 lL 6N HCl was added to 10 mg of dried and pulverized tissue, and hydrolyzed at 118 • C for 18 hours. This was neutralized using 120 lL 10 mol/L sodiumhydroxide. Hydroxyproline was measured in the supernatant after centrifugation as described [31] . The collagen content was calculated from total hydroxyproline using 7.46 as correction factor.
Detection of fibronectin by Western blotting
Kidneys from 34-week-old mice of each genotype (N = 5-7 in every group) were collected. Ten mg dried, defatted, pulverized tissue was dissolved in 150 lL extraction buffer [80 mmol/L Tris-HCl (pH 6.8), 4% sodium dodecyl sulfate (SDS), 5% mercaptoethanol, 1.7 mmol/L PMSF] and incubated at 37 • C for 1 hour, 100 • C for 3 minutes, followed by centrifugation (12,000 rpm, 15 minutes, 4 • C). The protein content was measured as described [32] . Two identical 7% SDS gels were loaded with 20 lg protein. After electrophoresis, one gel was transferred to a polyvinylidene fluoride (PVDF) membrane while the other was stained with Coomassie blue to ascertain equal loading. Immunoblotting was done by exposing the membrane to rabbit anti-fibronectin antibody (1:3000; Biogenesis) followed by hydrogen peroxidase (HRP) labeled goat antirabbit antibody (1:50,000; Santa Cruz Biotechnology). The blot was developed by the means of chemiluminiscence (Perbio, Rockford, IL, USA) and quantitated using Labworks 4.5 (UVP, Upland, CA, USA). The amount of fibronectin in the samples on each gel was standardized to the PAI-1-WT TGF-b1− and PAI-1-KO TGF-b1− groups and the amount of protein measured from the Coomassie blue gel.
Assessement of PAI-1, TGF-b1, big-h3, and ECM expression by quantitative real-time RT-PCR
Ten-(N = 5-8 in each group) and 34- week (N = 9-10 in each group)-old mice of each genotype were sacrificed. The kidneys were removed, halved, and total RNA from half a kidney was isolated using Trizol (Invitrogen, Carlsbad, CA, USA). After DNAse treatment, 2 lg of RNA was reverse transcribed by Superscript III using random hexamer primers according to the instructions by the supplier (Invitrogen). Real-time polymerase chain reaction (PCR) was performed and analyzed by the iCycler TM equipment and software (Bio-Rad, Hercules, CA, USA). The following primers were used: PAI-1: forward: GAG TGG CCT GCT AGG AAA TCC ATT C; reverse: GAC CTT GCC AAG GTG ATG CTT GGC AAC. Fibronectin: forward: GTG GCT GCC TTC AAC TTC TC; reverse: GTG GGT TGC AAA CCT TCA AT. Procollagen type I a1: forward: TGT TCG TGG TTC TCA GGG TAG; reverse: TTG TCG TAG CAG GGT TCT TTC. Procollagen type III a2: forward: GAG GAA ACA GAG GTG AAA GA; reverse AAC CAA GTA TTC TCC ACT CTT. TGF-b1: forward: ACC TTG GTA ACC GGC TGC; reverse: TCC TTG GTT CAG CCA CTG C. big-h3: forward: TCCTTGCCTGC-GAAGTG; reverse: GGA GAG CAT TGA GCA GTT CGA. GAPDH: forward: ATG TTC CAG TAT GAC TCC ACT CAC G; reverse: GAA GAC ACC AGT AGA CTC CAC GAC A.
All reactions were performed under the same conditions, 95 • C for 5 minutes followed by 35 to 45 cycles of 95 • C for 30 seconds, 60 • C for 1 minute, and 72 • C for 45 seconds, using SYBR green (Bio-Rad). Samples of cDNA from all mice were mixed and a standard curve (1:5, 1:50, 1:500) was included in each PCR reaction. The results were located within the standards in all reactions and the PCR efficiency was 95% to 105%, otherwise we repeated the PCR reaction. Each sample was analyzed in duplicate and the mean concentration was calculated. The ratio to the GAPDH quantity, analyzed in parallel, was computed and normalized to the PAI-1 WT TGF-b1−.
Detection of TGF-b1 in kidney homogenates
The renal content of TGF-b1 was determined in 34-week-old mice of each genotype (mice used for RT-PCR). Frozen tissue pieces were homogenized in Hank's balanced salt solution, the homogenate was filtered through a 100 lm filter, and centrifuged at 12,500 rpm (4 • C) [33] . The total protein content was measured by the MicroBCA kit (Pierce, Rockford, IL, USA). We used an enzyme-linked immunosorbent assay (ELISA; Quantikine, R&D Systems, Oxon, UK) to measure total TGF-b1 (with acidification) and free TGF-b1 (without acidifi-cation). The inter-and intra-assay variations were 9.8% to 12.8% and 3.7% to 7.3%, respectively.
Determination of the plasmin activity in renal extracts
Frozen kidneys from 10-week-old mice of each genotype (N = 5-7 in each group) were ground into powder in liquid nitrogen, and were mixed with 1 mL of 50 mmol/L Tris pH 8.2, 0.1% Triton X-100, followed by incubation for five minutes on ice. The supernatant was collected and frozen after centrifugation (10,000 rpm for 10 minutes). The total protein content was measured by the Mi-croBCA kit (Pierce). A total of 100 lg protein in a final volume of 160 lL in 50 mmol/L Tris, 100 mmol/L NaCl, 0,1% Triton X-100 was added 40 lL of the Chromozym PL substrate (3 mmol/L; Roche, Indianapolis, IN, USA), which upon cleavage by serine proteases, predominantly plasmin, is chromogenic. The absorbance was measured at 415 nm three times over four hours. A plasmin standard (Sigma-Aldrich) was used for the standard curve. To assess the plasminogen converting activity of u-PA and t-PA, 5 mU plasminogen (Sigma-Aldrich) was added, and the assay performed as above.
Determination of the MMP activity in renal extracts
Kidneys from 10-week-old mice of each genotype were collected (N = 3-5 in each group). The wet weight was recorded. The samples were homogenized in 50 mm Tris/HCl (pH 7.4) with 10 mmol/L CaCl 2 , 0.05% Brij 35, and 1 mmol/L PMSF overnight at 4 • C. Following centrifugation, the pellet was re-extracted overnight at 4 • C, followed by three heat extractions (60 • C for 4 minutes). The extracts from each animal (in total 40 lL per mg wet weight) were pooled and subjected to gelatin zymography as described [31] . Extracts were diluted four-fold with sample buffer (2% SDS, 10% glycerol, 0.05% bromophenol blue, 62.5 mmol/L Tris/HCl, pH 6.8), incubated at 37 • C for 15 minutes and loaded onto the gels (3.5 lL extract ( extract of 0.09 mg tissue per lane). Each gel was loaded with extracts from two mice from each group together with combined MMP-2 (Biogenesis) and MMP-9 standards [34] (5 and 40 pg of each enzyme). Each extract was repeatedly run on five gels. Following electrophoresis, the gels were washed in 2.5% Triton X-100 for 2 × 15 minutes. After a brief wash (1 lmol/L ZnCl 2 , 5 mmol/L CaCl 2 , 10 mmol/L Tris/HCl, pH 7.5), the gels were incubated in this buffer further added 25 lmol/L PMSF at 37 • C for 20 hours under gentle agitation. Thereafter, the gels were stained with 0.1% Coomassie blue in 30% methanol/10% acetic acid, destained, and scanned using a Shimadzu Chromato Scanner (CS-930; Shimadzu, Kyoto, Japan). Batsed on color scan areas, the amounts of enzymes in the extracts were determined by interpolation using the scan areas of the MMP-2 and MMP-9 standards in the same gel and pg per mg wet weight was calculated. To test for the presence of collagenase activity in the kidney extracts, triple-helical collagen degradation for 1 week at 26 • C was performed as previously described in details [35] .
In situ zymography using FITC-labeled substrate
To localize the collagen degrading activity in the kidneys, in situ zymography was performed as described [36] . In short, the kidneys were removed from 16-weekold mice of each genotype (N = 2-3 in each group). An FITC-labeled quenched gelatin substrate (1 mg/mL) (Molecular Probes, Eugene, OR, USA) was mixed with 1% agarose in 50 mmol/L Tris HCl, 150 mmol/L NaCl, 5 mmol/L CaCl, and 0.05% Brij35. The solution was allowed to gel on preheated microscopic glass slides. A 6-lm frozen tissue section was placed on the gel, reaction buffer containing PMSF was added, and the section was placed in a humidified chamber at 37 • C for one to two hours. Collagen degrading activity was observed as green fluorescence on the section. Ten mmol/L EDTA and 1 mmol/L 1,10-phenanthroline were added the sections to inhibit the reaction.
Statistical analysis
All data are given as mean and coefficient of variance (CV = SD/mean). When all 4 genotypes were compared, analysis of variance (ANOVA) was applied utilizing the Student-Newman-Keuls test for multiple comparisons. In case of unequal variance the Kruskal-Wallis test followed by Mann-Whitney nonparametric test for multiple comparisons was used. To test the impact of TGF-b1, irrespective of PAI-1 genotype, a univariate general linear model analysis (GLM) was applied. P < 0.05 was regarded as statistically significant. Data were tested for outliers.
RESULTS

Functional data, PAI-1, big-h3, and TGF-b1 expression
The body weight and kidney weight/body weight ratio were similar in the four genotypes at 10, 16, and 34 weeks of age. No difference in water intake, urine output, or urinary albumin:creatinine ratio was observed. The albumin:creatinine ratio of 16-week-old mice are shown in Table 1 . PAI-1 mRNA was higher in the PAI-1 WT TGF-b1+ mice versus the PAI-1 WT TGF-b1− animals, which supports that PAI-1 expression is induced by TGF-b1 ( Fig. 1A) . As expected, PAI-1 mRNA was absent in PAI-1 KO mice ( Fig. 1 ). PAI-1 expression, as visualized by IHC, was present in the glomeruli of PAI-1 WT TGF-b1+ mice (N = 4), whereas PAI-1 WT TGF-b1− mice (N = 4) and PAI-1 KO [TGF-b1+ (N = 4) and TGF-b1− (N = 4)] mice had little or no PAI-1 immunostaining, respectively ( Fig. 1B) .
At 10 weeks of age, the TGF-b1 mRNA tended to be higher in PAI-1 WT TGF-b1+ and PAI-1 KO TGF-b1+ mice versus PAI-1 WT TGF-b1− and PAI-1 KO TGF-b1−, respectively ( Fig. 2A) . The GLM demonstrated an effect of the transgene on endogenous TGF-b mRNA levels (P = 0.01). At 34 weeks of age, the TGF-b1 mRNA was higher in PAI-1 WT TGF-b1+ versus PAI-1 WT TGF-b1− (P = 0.02) ( Fig. 2A) . Again, the GLM showed that the transgene significantly increased the TGF-b1 mRNA amount (P = 0.01). PAI-1 deficiency did not change the TGF-b1 mRNA level ( Fig. 2A) .
At 10 weeks of age, the big-3h mRNA showed a borderline increase in PAI-1 KO TGF-b1+ mice versus PAI-1 KO TGF-b1− (P = 0.06) (Fig. 2B) . The GLM demonstrated an effect of both the transgene and PAI-1 deficiency on big-h3 mRNA levels (P = 0.01 and P = 0.03, respectively). At 34 weeks of age, the big-3h mRNA was higher in PAI-1 WT TGF-b1+ versus PAI-1 WT TGF-b1− (P < 0.05) (Fig. 2B) . Again, the GLM showed that the transgene significantly increased the big-3h mRNA amount (P = 0.01). At this age there was no effect of PAI-1 deficiency on big-h3 mRNA levels as estimated by GLM.
At 10 and 34 weeks of age the big-h3:TGF-b1 ratio was similar in the four groups of mice (Fig. 2C) . However, the GLM demonstrated a trend toward higher big-h3:TGF-b1 ratio in PAI-1 KO versus PAI-1 WT animals (P = 0.07).
There was a tendency to higher levels of free TGF-b1 in the 34-week-old transgenic mice: PAI-1 WT TGF-b1−: . After acidification and neutralization, total TGF-b1 could not be detected in many of the tissue homogenates due to the necessary dilution (data not shown)
Glomerular morphology, glomerular number, glomerular volume, BMT, Vv(mes/glom), and Vv(mes/tuft)
As seen by light microscopy the PAI-1 WT TGF-b1+ mice developed deposits of PAS-positive material in the mesangial area of the glomeruli. This was reduced by PAI-1 deficiency (Fig. 3A) .
The glomerular number was unaffected by TGF-b1 expression and PAI-1 deficiency: PAI-1 WT TGF-b1−: 14.5 × 10 3 (0.13) (N = 6); PAI-1 WT TGFb1+: 14.9 × 10 3 (0.16) (N = 5); PAI-1 KO TGF-b1−: 13.1 × 10 3 (0.10) (N = 5); PAI-1 KO TGF-b1+: 14.4 × 10 3 (0.24) (N = 5).
The glomerular volume was similar in the four groups of mice at 10 and 16 weeks of age ( Table 1) .
The BMT in 10-and 16-week-old PAI-1 WT TGF-b1+ mice was elevated versus the age-matched PAI-1 WT TGF-b1− animals (both P < 0.05) ( Table 1 , Fig. 3 ), whereas the BMT in PAI-1 KO TGF-b1+ was marginally increased versus PAI-1 KO TGF-b1− only in 16-weekold mice (P = 0.054). Importantly, at 16 weeks of age the BMT was 172 nm (0.13) in the PAI-1 WT TGF-b1+ versus 152 nm (0.11) in the PAI-1 KO TGF-b1+ (P < 0.05). These data suggest that TGF-b1 increases the BMT while PAI-1 deficiency attenuates this enlargement.
The Vv(mes/tuft) was increased in 10-week-old PAI-1 WT TGF-b1+ versus PAI-1 WT TGF-b1− mice (P < 0.05) ( Table 1) . No other statistically significant changes were observed in Vv(mes/tuft) or Vv(mes/glom) in this age group of mice. Both the Vv(mes/tuft) and Vv(mes/glom) were increased in 16-week-old PAI-1 WT TGF-b1+ mice versus PAI-1 WT TGF-b1− animals (both P < 0.05). On the other hand, only the Vv(mes/tuft) was statistically significant increased in PAI-1 KO TGF-b1+ versus PAI-1 KO TGF-b1− (Table 1) . Interestingly, both the Vv(mes/glom) and Vv(mes/tuft) were higher in PAI-1 WT TGF-b1+ mice versus PAI-1 KO TGF-b1+ (both P < 0.05). Thus, these data suggest that TGF-b1 increases the Vv(mes/tuft) and Vv(mes/glom), while PAI-1 deficiency hinders this enlargement. By immunohistochemistry, we demonstrated that the accumulated mesangial ECM in PAI-1 WT TGF-b1+ mice and PAI-1 KO TGF-b1+ mice consisted of fibronectin (not shown), collagen IVa1-2, and laminin, whereas collagen type I and III were absent (Fig. 3) . Normal laminin b2 staining in the GBM was seen in all mice.
RNA expression of ECM molecules
The transcription of collagen types I and III was increased in the PAI-1 WT TGF-b1+ mice versus the PAI-1 WT TGF-b1− in early (10 weeks) and late (34 weeks) disease (all P < 0.05) (Fig. 4) . In the aged mice it is noteworthy that the collagen type I mRNA expression was higher in the PAI-1 WT TGF-b1+ [2.1 (N = 10)] versus the PAI-1 KO TGF-b1+ mice [1.1, (N = 9)] (P < 0.05). Fibronectin mRNA was elevated during late disease (34 weeks) (P < 0.05). The only statistically significant observation in the PAI-1 KO mice was an increase in collagen type I expression in 10-week-old TGF-b1+ mice versus TGF-b1− animals (P < 0.05) (Fig. 4) . Thus, our data imply that PAI-1 KO not only influences the degradation of ECM but may influence ECM synthesis as well.
Total collagen content
In 16-week-old-mice the total collagen content only tended to be higher in the PAI-1 WT TGF-b1+ mice versus the PAI-1 WT TGF-b1− group and the PAI-1 KO TGF-b1+ group (P = 0.069) ( Fig. 5 ). However, the collagen deposition increased with age in the TGF-b1+ mice. Thus, at 34 weeks of age the amount of collagen was statistically significant elevated in both TGF-b1+ groups versus the TGF-b1− groups (both P < 0.05). Furthermore, the increase in collagen quantity was more marked in the PAI-1 WT TGF-b1+ mice [61.0 lg collagen/mg dry weight (0.12)] versus the PAI-1 KO TGF-b1+ mice [46.8 lg collagen/mg dry weight (0.20)] (P < 0.05) (Fig. 5) . These data suggest that TGF-b1 increases the total renal collagen content while PAI-1 deficiency slows down the deposition of collagen.
Fibronectin content
The data showed that the fibronectin quantity was increased in 34-week-old PAI-1 WT TGF-b1+ mice compared with PAI-1 WT TGF-b1− and PAI-1 KO TGF-b1+ mice (both P = 0.01) (Fig. 6 ).
Localization of ECM molecules
Collagen type III, which was almost absent in the TGF-b1− mice of both PAI genotypes, was present in many areas of the cortex in TGF-b1+ mice, especially the PAI-1 WT (Fig. 7) . Collagen type I deposits were similar in PAI-1 WT TGF-b1− and PAI-1 KO TGF-b1− animals and seemed increased in the cortical region of the TGF-b1+ mice. The increase was more evident in the PAI-1 WT TGF-b1+ mice. The staining for collagen type IV and fibronectin showed that both components were present in all four genotypes of mice without any obvious differences (not shown).
Macrophage infiltration
No or very few activated macrophages were detected in mice of the four different groups [PAI-1 WT TGF-b1+ (N = 4), PAI-1 WT TGFb1− (N = 4), PAI-1 KO TGF-b1+ (N = 4), and PAI-1 KO TGF-b1− (N = 4)] (data not shown).
Plasmin activity
The plasmin activity in renal extracts was similar among the four different genotypes of mice (Fig. 8A) . To investigate the collective action of t-PA and u-PA, the plasmin activity was determined after addition of plasminogen. Again, no obvious differences between the four different genotypes of mice were discovered (Fig. 8B) . We found no effect of TGF-b1 on plasmin or PA activity as estimated by GLM.
Gelatin zymography
Gelatin zymography demonstrated both MMP-2 and MMP-9 activity. Transforming growth factor-b1 significantly increased the MMP-2 amount (GLM, P < 0.05), while 0the MMP-9 was unchanged ( Fig. 9 ). PAI-1 deficiency did not change the gelatinase level.
Collagenase activity
Degradation experiments did not indicate any presence of collagenase activity in the extracts. This is in agreement with the absence of zymographic lysis bands below the MMP-2 bands.
In situ zymography
The most significant part of gelatin degrading activity was localized around the tubular basement membrane and the tubulointerstitial space, while lesser protease activity was seen in the glomeruli (Fig. 10) . No obvious difference was observed between the four genotypes of mice in the interstitium (N = 2-3 in each group). The glomeruli of PAI-1 WT TGF-b1+ and PAI-1 KO TGF-b1+ mice exhibited no or only very faint fluorescent signals (Fig. 10) , which suggests that TGF-b1 reduces protease activity specifically in the glomeruli. 1,10-phenanthroline in combination 10 mmol/L EDTA was able to inhibit all substrate degradation.
DISCUSSION
Our main findings are the following. First, PAI-1 WT TGF-b1+ mice exhibit augmented PAI-1 mRNA expression versus TGF-b1− animals. Second, PAI-1 KO attenuates TGF-b1-induced BMT, mesangial expansion, collagen type I and III mRNA expression, as well as total collagen accumulation. Third, in our model PAI-1 deficiency does not alter plasmin and PA activity or the MMP amount. Finally, younger PAI-1 KO mice had a tendency to a higher level of active/free TGF-b1. Our data suggest that some of the biological effects of TGF-b1 on ECM homeostasis are mediated through PAI-1 by as yet unknown pathways.
Several investigators have used different methods to address the role of PAI-1 in the pathogenesis of kidney disease. However, the results have been somewhat inconsistent. Three studies have employed rapidly progressive models of kidney disease in PAI-1 genedeficient mice; two showed positive effects of PAI-1 KO in models employing ureteral obstruction and crescentic glomerulonephritis, respectively, whereas the third study demonstrated an accelerated disease progression in antiglomerular basement membrane glomerulonephritis [16, 17, 37] . In line with the former two observations did PAI-1 blockage by a nonfunctional PAI-1 competitor attenuate anti-thy1-induced glomerular nephritis [24] . The utilized models all have a rapid developing disease progression that contains a significant inflammatory component. Protective as well as aggravating effects of PAI-1 deficiency are linked to a possible immunoregulatory role of PAI-1 on macrophage migration and TGF-b1 activation, respectively.
In the present investigation we showed that PAI-1 KO approximately halves the ECM accumulation in a slowly progressive, TGF-b1-induced renal disease that lacks a major inflammatory component. Thus, the effect of PAI-1 KO in our study is unlikely to be related to an immunomodulatory effect of PAI-1. More likely, the beneficial effect of PAI-1 KO may be due to a direct influence on the ECM homeostasis, collagen type I in particular. This idea is supported by the finding of reduced collagen type I and III mRNA levels in the PAI-1 KO TGF-b1+ mice versus PAI-1 WT TGF-b1+ animals. This signifies that PAI-1 in itself or by secondary mediators might influence ECM synthesis. PAI-1 might interfere with cellular integrin binding to vitronectin, thereby modulating the expression of different components of the ECM [38, 39] . Early after the discovery of the ability of TGF-b1 to induce PAI-1 expression, it was suggested that part of the profibrotic effect of TGF-b1 was mediated through diminution of the plasmin system [19] . However, we did not find evidence supporting that the positive effect of PAI-1 KO on TGF-b1-induced fibrosis could be explained by altered protease activity. The plasmin activity in kidney extracts with or without added plasminogen was similar in the four groups of mice. This observation is comparable to other studies in which the plasmin activity was unchanged or even decreased in PAI-1 KO mice versus WT controls [16, 17] . One explanation may be a compensatory increase in other inhibitors of PA, for example PAI-2 or PAI-3. Another possible explanation is that measurement of plasmin activity on whole kidney extract veils the very delicate local balance between plasmin activators, plasmin inhibitors, and their substrates. This is supported by our observation of different protease activity in the glomeruli and interstitium by in situ zymography.
That the effect of PAI-1 KO may be independent of plasmin activity is supported by the finding that both t-PA and plasminogen gene knockout attenuate the interstitial fibrosis in a model of obstructive nephropathy [15, 40] . Surprisingly, the investigation showed that t-PA-deficient mice had decreased MMP-9. The diminished fibrosis was explained by decreased epithelial mesenchymal transformation [40] . It is generally believed that plasmin and PAI-1 act through recruitment of macrophages. As mentioned above, macrophages are rare in our model. However, macrophages do not always promote fibrosis, as seen in angiotensin II type 1 receptor deficient mice, which show exaggerated fibrosis response with fewer macrophages compared to wild-type mice [41] .
We measured the MMPs by zymography, and only MMP-2 and MMP-9 were readily detectable. TGF-b1 increased the total amount of MMP-2, while MMP-9 was unchanged. PAI-1 genotype did not affect MMP-2 or MMP-9 expression. This is in line with a previous study that showed TGF-b1 increased MMP-2 activity in vitro [42, 43] . Again, one has to remember that MMP activity in vivo may be localized to specific microcompartments in the kidney and, thus, could be different from the findings ex vivo by gel zymography. Therefore, we performed in situ zymography to visualize the localization of the gelatin degrading activity. We found that most of the gelatinase activity was localized around the tubuli. There was no apparent difference between PAI-1 KO and WT animals. This is in line with the data obtained by gel zymography. An interesting finding was that irrespective of PAI-1 genotype, the gelatin-degrading activity was almost absent in the glomeruli of the TGF-b1 transgenic mice compared with nontransgenic animals. This could very well account for some of the glomerular matrix accumulation in transgenic mice. The finding of decreased gelatinase activity in the glomeruli may seem to conflict with the finding of increased MMP-2 on whole kidney extracts in TGF-b1+ mice. However, the glomeruli only constitute a small part of the total kidney volume, and a decrease in glomerular MMP-2 activity would easily be outweighed by an increase of protease activity in the tubulointerstitium. Furthermore, the in situ zymography only illustrates active proteases, while gel zymography measures protein amount. While we were unable to demonstrate any effect of PAI-1 KO on protease expression, we cannot exclude that PAI-1 modulate the metabolism of other MMPs. The GBM became approximately 33% thicker during exposure to TGF-b1+ in vivo. Yet the mice did not develop albuminuria. When the transgene is expressed on the genetic background of Balb/c mice we have found that albumin excretion is increased in parallel with the development of glomerular changes [6] . However, TGF-b1induced kidney disease has an accelerated progression in Balb/c mice. Such a strain-dependent susceptibility to glomerulosclerosis is well known [44] . It is evident that the attenuated progression of TGF-b1-induced kidney disease in the PAI-1 KO mice could be explained by altered expression and activation of endogenous TGF-b1 due to PAI-1 deficiency. In early and late disease states we were unable to detect any differences in TGF-b1 mRNA between WT and PAI-1 KO animals. However, similar to findings by Edgtton et al [15] , PAI-1 deficiency tended to increase the expression of the TGF-b1-responsive gene big-h3 and raise the big-h3:TGF-b1 ratio in young mice. It has been reported that plasmin independent but PA-dependent activation of TGF-b1 takes place in vitro and in vivo [17] . It should be considered, however, that the latter takes place only after induction of anti-thy-1-mediated glomerulonephritis [17] . Similar to Hertig et al, we found no difference in active TGF-b1 in nontransgenic WT and PAI-1 KO mice [17] . Thus, it is unlikely that it is through altered TGF-b1 processing that the TGF-b1-induced kidney disease is alleviated in PAI-1 KO mice.
We have shown that PAI-1 gene deficiency attenuates TGF-b1-induced kidney disease, decreasing both glomerular and interstitial ECM deposition. We could not find evidence supporting the hypothesis that the effect was mediated through increased MMP and protease activity. On the other hand, our data point in the direction that PAI-1 KO decreases ECM synthesis. We conclude that PAI-1 mediates some of TGF-b1's biological effects in vivo. It will be important in the future to investigate the effect of PAI-1 on ECM metabolism further.
